Table 1 Tumor and nontumor derived EV cargoes affecting tumor progression
From: The role of extracellular vesicles in circulating tumor cell-mediated distant metastasis
EV Source | Cargo | Pathway | Effect | Reference |
|---|---|---|---|---|
CRC cell | miR-4299 | Regulate target gene ZBTB4 | Promote tumor proliferation and metastasis | Wu et al. (2023) [21] |
| Â | miR-224-5p | Downregulate CMTM4 | Promote tumor progression | Wu et al. (2022) [22] |
| Â | miR-361-3p | Target TRAF3-mediated noncanonical NF-kB pathway | Promote tumor progression and proliferation | Li et al. (2021) [23] |
|  | circPACRGL | Via miR-142-3p/miR-506-3p-TGF-β1 axis | Promote tumor progression | Shang et al. (2020) [24] |
Gastric cancer cell | c-Myc | Via the KCNQ1OT1/miR-556-3p/CLIC1 axis | Promote tumor growth and metastasis | Li et al. (2022) [25] |
|  | TGF-β | Via the TGF-β/Smad pathway | Promote tumor growth | Gu et al. (2012) [26] |
HCC cell | lncRNA SNHG16 | Via the miR-942-3p/MMP9 axis | Promote tumor metastasis | Xu et al. (2023) [27] |
Lung cancer cell | PKM2 | Via the AMPK pathway | Promote tumor progression | Zhou et al. (2022) [28] |
Lung adenocarcinoma cell | circRAPGEF5 | Via miR-1236-3p/ZEB1 axis | Promote the proliferation and metastasis of lung adenocarcinoma | Zhou et al. (2022) [29] |
| Â | miR-31-5p | Decrease SATB2 expression and increase MEK/ERK pathway activity | Promote tumor progression | Yu et al. (2021) [30] |
TNBC cell | EphA2 | Downregulate ZO-1 and activated the RhoA pathway in endothelial cells | Promote tumor metastasis | Liu et al. (2023) [31] |
Renal cell carcinoma cell | lncRNA MALAT1 | Regulate transcription factor ETS1 and affect TFCP2L1 activity | Promote the invasion and migration of renal cell carcinoma | Jin et al. (2021) [32] |
Glioma cell | WT1 | Via EV-mediated WT1-Thbs1 intercellular regulatory pathway | Promote tumor progression | Tsutsui et al. (2020) [33] |
| Â | miR-3184-3p | Promote M2 macrophage polarization | Promote tumor progression | Xu et al. (2022) [34] |
|  | SBSN | Activate the NF-κB pathway | Promote tumor progression | Chen et al. (2022) [35] |
Glioblastoma cell | VEGF-A | Interrupt the expression of claudin-5 and occludin | Promote tumor progression | Zhao et al. (2018) [36] |
Pancreatic cancer cell | FGD5-AS1 | Lead to M2 macrophage polarization | Promote tumor progression | He et al. (2022) [37] |
| Â | circPDK1 | Sponge miR-628-3p to activate the BPTF/c-myc axis | Promote tumor progression | Lin et al. (2022) [38] |
BC cell | miR-1910-3p | Target MTMR3 and activate the NF-κB signaling pathway | Promote tumor progression | Wang et al. (2020) [39] |
Prostatic cancer cell | circFMN2 | Via repression of KLF2/RNF128 | Promote the proliferation, invasion and migration of prostatic cancer | Huang et al. (2023) [40] |
Ovarian cancer cell | miR-106a-5p | Target KLF6 | Promote the proliferation and metastasis of ovarian cancer | Zheng et al. (2022) [41] |
| Â | miR-205 | Target VEGFA | Promote the proliferation, invasion and migration of ovarian cancer | Wang et al. (2019) [42] |
Cervical cancer cell | miR-423-3p | Suppress macrophage M2 polarization | Inhibit the progression of cervical cancer | Yan et al. (2022) [43] |
Endometrial cancer cell | LGALS3BP | Activate the PI3K/AKT/VEGFA signaling pathway | Promote the proliferation and migration of endometrial cancer | Song et al. (2021) [44] |
CAFs* | miR-181b-3p | Regulate SNX2 expression | Promote the proliferation and migration of CRC | Jiang et al. (2022) [45] |
| Â | miR-625-3p | Inhibit the CELF2/WWOX pathway | Promote the progression of CRC | Zhang et al. (2022) [46] |
|  | miR-1290 | Target GSK3β | Promote the growth and metastasis of prostate cancer | Wang et al. (2022) [47] |
| Â | miR-18b | Regulate TCEAL7 | Promote the invasion and metastasis of breast cancer | Yan et al. (2021) [48] |
| Â | circEIF3K | Via miR-214/PD-L1 axis | Promote the progression of CRC | Yang et al. (2021) [49] |
| Â | LncRNA LINC00659 | Via miR-342-3p/ANXA2 axis | Promote the proliferation and migration of CRC | Zhou et al. (2021) [50] |
MSCs* | miR-598 | Target THBS2 | Inhibit the proliferation and migration of NSCLC | Li et al. (2023) [51] |
| Â | miR-100 | Via the miR-100/mTOR/miR-143 axis | Inhibit the progression of CRC | Jahangiri et al. (2022) [52] |
| Â | miR-744-5p | Inhibit M2 polarization of macrophages | Inhibit the progression of glioma | Liu et al. (2022) [53] |
| Â | miR-503-3p | Downregulate MEST | Inhibit the progression of human endometrial cancer | Pan et al. (2022) [54] |
| Â | miR-199a | Downregulate AGAP2 | Inhibit the progression of glioma | Yu et al. (2019) [55] |
| Â | miR-1587 | Downregulate the tumor-suppressor NCOR1 | Promote the growth and proliferation of glioma | Figueroa et al. (2017) [56] |
BMSCs* | LncRNA XIST | Via the miR-655/ACLY signal | Promote the growth and metastasis of osteosarcoma | Zhu et al. (2022) [57] |
| Â | NEAT1 | Induce M2 macrophage polarization | Promote the progression of melanoma | Yang et al. (2022) [58] |
|  | miR-342-3p | Inhibit the INHBA/IL13Rα2 axis | Inhibit the growth and metastasis of breast cancer | Liu et al. (2022) [59] |
| Â | miR-328-3p | Inhibit the Hippo pathway | Promote the progression of lung cancer | Liu et al. (2021) [60] |
| Â | miR-144 | Downregulate CCNE1 and CCNE2 | Inhibit the progression of NSCLC | Liang et al. (2020) [61] |
| Â | miR-205 | Inhibit RHPN2 | Inhibit the progression of prostate cancer | Jiang et al. (2019) [62] |
TAM | miR-95 | Bind to downstream target gene JunB | Promote the proliferation and invasion of prostate cancer | Guan et al. (2020) [63] |
Platelets* | ITGβ3 | Inhibit ferroptosis | Promote the metastasis of nasopharyngeal carcinoma | Li et al. (2022) [64] |
| Â | miR-24 | Target mitochondrial mt-Nd2 and Snora75 | Suppress solid tumor growth | Michael et al. (2017) [65] |
| Â | miR-223 | Target tumor suppressor EPB41L3 | Promote the invasion of lung cancer | Liang et al. (2015) [66] |
NK cell* | miR-let-7b-5p | Target the cell cycle regulator CDK6 | Inhibit the proliferation of pancreatic cancer cells | Di Pace et al. (2023) [67] |
|  | miR-186 | Induce inhibition of TGFβ signaling | Inhibit the growth of neuroblastoma | Neviani et al. (2019) [68] |
CD8+ T* cell | miR-765 | Suppress PLP2 expression | Inhibit the progression of uterine corpus endometrial cancer (UCEC) | Zhou et al. (2021) [69] |